Consensus provides clinical guidance for individualized treatment of HR-positive breast cancer, suggesting precision in therapy.
This consensus may provide clinical guidance for the standardized application of ET, thereby facilitating precise and individualized treatment for HR-positive breast cancer.
No takes yet. Share an insight, caveat, or question.
Therapy et al. (2026) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: